Comparative Pharmacology
Head-to-head clinical analysis: ENOXAPARIN SODIUM PRESERVATIVE FREE versus INNOHEP.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENOXAPARIN SODIUM PRESERVATIVE FREE versus INNOHEP.
ENOXAPARIN SODIUM (PRESERVATIVE FREE) vs INNOHEP
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Enoxaparin binds to antithrombin III (ATIII), accelerating its inhibition of coagulation factors Xa and IIa (thrombin). Its anti-factor Xa to anti-factor IIa activity ratio is approximately 3.6:1.
Tinzaparin is a low molecular weight heparin that binds to antithrombin III, accelerating its inhibition of factor Xa and thrombin (factor IIa), thereby exerting anticoagulant effects.
1 mg/kg subcutaneously every 12 hours or 1.5 mg/kg subcutaneously once daily. For prophylaxis: 40 mg subcutaneously once daily or 30 mg subcutaneously every 12 hours.
Subcutaneous administration: 2500 IU anti-Xa (0.25 mL) once daily for low to moderate risk of thromboembolism; 3500 IU anti-Xa (0.35 mL) once daily for high risk. For treatment of deep vein thrombosis (DVT): 175 IU anti-Xa/kg body weight once daily by subcutaneous injection. Maximum dose: 17,500 IU per day.
None Documented
None Documented
Terminal elimination half-life is 4.5 hours after subcutaneous administration based on anti-Factor Xa activity; prolonged to 6-7 hours in renal impairment (CrCl <30 mL/min).
Terminal half-life 3-4 hours; clinical context: once-daily dosing provides sustained anti-Xa activity.
Renal excretion of anti-Factor Xa activity accounts for approximately 40% of total clearance; a small fraction undergoes biliary/fecal elimination (<10%).
Primarily renal; 40-50% of the dose excreted unchanged in urine; minor biliary/fecal elimination.
Category A/B
Category C
Low Molecular Weight Heparin
Low Molecular Weight Heparin